Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hidradenitis Suppurativa Overview 6 Therapeutics Development 7 Pipeline Products for Hidradenitis Suppurativa - Overview 7 Hidradenitis Suppurativa - Therapeutics under Development by Companies 8 Hidradenitis Suppurativa - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Hidradenitis Suppurativa - Products under Development by Companies 12 Hidradenitis Suppurativa - Companies Involved in Therapeutics Development 13 Cellceutix Corporation 13 Celtaxsys, Inc. 14 Delenex Therapeutics AG 15 Johnson & Johnson 16 Novartis AG 17 Sandoz International GmbH 18 Hidradenitis Suppurativa - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 acebilustat - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 adalimumab biosimilar - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 adalimumab biosimilar - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 brilacidin tetrahydrochloride - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 CJM-112 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 DLX-105 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 DLX-2751 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ustekinumab - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Xilonix - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Hidradenitis Suppurativa - Dormant Projects 59 Hidradenitis Suppurativa - Discontinued Products 60 Hidradenitis Suppurativa - Product Development Milestones 61 Featured News & Press Releases 61 Sep 11, 2014: Delenex Announces New Clinical Data 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63

List of Tables Number of Products under Development for Hidradenitis Suppurativa, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Hidradenitis Suppurativa - Pipeline by Cellceutix Corporation, H2 2016 13 Hidradenitis Suppurativa - Pipeline by Celtaxsys, Inc., H2 2016 14 Hidradenitis Suppurativa - Pipeline by Delenex Therapeutics AG, H2 2016 15 Hidradenitis Suppurativa - Pipeline by Johnson & Johnson, H2 2016 16 Hidradenitis Suppurativa - Pipeline by Novartis AG, H2 2016 17 Hidradenitis Suppurativa - Pipeline by Sandoz International GmbH, H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Hidradenitis Suppurativa - Dormant Projects, H2 2016 59 Hidradenitis Suppurativa - Discontinued Products, H2 2016 60 List of Figures Number of Products under Development for Hidradenitis Suppurativa, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 10 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Targets, H2 2016 20 Number of Products by Stage and Targets, H2 2016 20 Number of Products by Mechanism of Actions, H2 2016 22 Number of Products by Stage and Mechanism of Actions, H2 2016 22 Number of Products by Routes of Administration, H2 2016 24 Number of Products by Stage and Routes of Administration, H2 2016 24 Number of Products by Molecule Types, H2 2016 26 Number of Products by Stage and Molecule Types, H2 2016 26

Cellceutix Corporation Celtaxsys, Inc. Delenex Therapeutics AG Johnson & Johnson Novartis AG Sandoz International GmbH